Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Andrei H. Iagaru

Radiology | Nuclear Medicine
Stanford Health Care
5555 W Las Positas Blvd, 
Pleasanton, CA 

Advanced in WT1-Related Wilms Tumor Syndromes
Stanford Health Care
5555 W Las Positas Blvd, 
Pleasanton, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Andrei Iagaru is a Radiologist and a Nuclear Medicine provider in Pleasanton, California. Dr. Iagaru is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Neuroendocrine Tumor, Osteopenia, Melorheostosis with Osteopoikilosis, Prostatectomy, and Tissue Biopsy.

His clinical research consists of co-authoring 224 peer reviewed articles and participating in 28 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiology
Nuclear Medicine
Licenses
Nuclear Medicine in CA
Hospital Affiliations
Stanford Health Care Tri-Valley
Stanford Health Care
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

STANFORD HEALTH CARE
5555 W Las Positas Blvd, Pleasanton, CA 94588
Call: 925-847-3000
Other Locations
STANFORD HEALTH CARE
450 Broadway St, Redwood City, CA 94063
Call: 650-723-4000
STANFORD HEALTH CARE
5800 Hollis St, Emeryville, CA 94608
Call: 510-806-2100
STANFORD HEALTH CARE
300 Pasteur Dr, Stanford, CA 94305
Call: 650-723-4000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


28 Clinical Trials

A Phase I/IIa Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Whole-body Distribution, Radiation Dosimetry and Anti-tumor Activity of [177Lu]-NeoB Administered in Patients With Advanced Solid Tumors Known to Overexpress Gastrin-releasing Peptide Receptor (GRPR)
A Phase I/IIa Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Whole-body Distribution, Radiation Dosimetry and Anti-tumor Activity of [177Lu]-NeoB Administered in Patients With Advanced Solid Tumors Known to Overexpress Gastrin-releasing Peptide Receptor (GRPR)
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, and Coronavirus Disease 2019 With [18F]FP-R01-MG-F2 With PET/CT
Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, and Coronavirus Disease 2019 With [18F]FP-R01-MG-F2 With PET/CT
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drug: [18F]FP-R01-MG-F2
Study Phase: Early Phase 1
18F-DCFPyL PET/MRI for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-risk Prostate Cancer
18F-DCFPyL PET/MRI for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-risk Prostate Cancer
Enrollment Status: Approved_for_marketing
Publish Date: December 19, 2024
Intervention Type: Drug, Procedure
Pilot Study of 89Zr Panitumumab in Pancreas Cancer
Pilot Study of 89Zr Panitumumab in Pancreas Cancer
Enrollment Status: Withdrawn
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Zr-89 Panitumumab
Study Phase: Phase 1
Evaluation of Patients With Low-Risk and Intermediate-Risk Prostate Cancer Scheduled for High-Dose Rate Brachytherapy Using 68-Ga-RM2 PET, 68Ga-PSMA-11 PET and Multi Parametric MRI
Evaluation of Patients With Low-Risk and Intermediate-Risk Prostate Cancer Scheduled for High-Dose Rate Brachytherapy Using 68-Ga-RM2 PET, 68Ga-PSMA-11 PET and Multi Parametric MRI
Enrollment Status: Terminated
Publish Date: February 01, 2024
Intervention Type: Drug, Device
Study Drugs: 68-Ga RM2., 68-Ga PSMA11
Study Phase: Phase 2
68Ga-NeoBOMB1 and 68Ga-PSMA R2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer
68Ga-NeoBOMB1 and 68Ga-PSMA R2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer
Enrollment Status: Completed
Publish Date: January 30, 2024
Intervention Type: Drug, Device
Study Drug: Gallium Ga 68 DOTA-NeoBOMB1
Study Phase: Phase 2
A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
Enrollment Status: Completed
Publish Date: January 11, 2024
Intervention Type: Drug, Device
Study Drugs: 68Ga RM2, 68Ga-PSMA-11
Study Phase: Phase 2
A Pilot Study of 68-Ga-RM2 PET/MRI in the Evaluation of Patients With Estrogen Receptor-Positive Breast Cancer
A Pilot Study of 68-Ga-RM2 PET/MRI in the Evaluation of Patients With Estrogen Receptor-Positive Breast Cancer
Enrollment Status: Completed
Publish Date: December 13, 2023
Intervention Type: Procedure, Drug, Device
Study Drug: Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
Study Phase: Phase 1/Phase 2
68Ga-RM2 PET/CT for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-Risk Prostate Cancer
68Ga-RM2 PET/CT for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-Risk Prostate Cancer
Enrollment Status: Completed
Publish Date: December 12, 2023
Intervention Type: Drug, Other, Procedure
Study Drug: Gallium Ga 68-Labeled GRPR Antagonist BAY86-7548
Study Phase: Phase 2
Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases
Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases
Enrollment Status: Completed
Publish Date: December 12, 2023
Intervention Type: Procedure, Drug
Study Phase: Phase 2
Detection of Integrin Alpha-v-Beta 6 in Pancreatic Cancer With [18F]-R01-MG-F2: a First in Human Study
Detection of Integrin Alpha-v-Beta 6 in Pancreatic Cancer With [18F]-R01-MG-F2: a First in Human Study
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug, Diagnostic test, Other
Study Drug: 18F FP-RO1-MG-F2
Study Phase: Early Phase 1
68Ga-RM2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-contributory CT Scans
68Ga-RM2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-contributory CT Scans
Enrollment Status: Completed
Publish Date: April 10, 2023
Intervention Type: Drug, Procedure
Study Drug: Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
Study Phase: Phase 2/Phase 3
Comparison of Standard PET/CT vs. Digital PET/CT
Comparison of Standard PET/CT vs. Digital PET/CT
Enrollment Status: Completed
Publish Date: April 12, 2022
Intervention Type: Diagnostic test
Study Phase: Not Applicable
68Ga-PSMA-11 PET/MRI for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-Risk Prostate Cancer
68Ga-PSMA-11 PET/MRI for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-Risk Prostate Cancer
Enrollment Status: Completed
Publish Date: March 04, 2022
Intervention Type: Procedure, Drug
Study Drug: Gallium Ga 68-PSMA-11
Study Phase: Phase 2/Phase 3
18F-DCFPyL PET/CT in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-Contributory CT Scans
18F-DCFPyL PET/CT in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-Contributory CT Scans
Enrollment Status: No_longer_available
Publish Date: January 21, 2022
Intervention Type: Other, Procedure, Radiation
68-Ga PSMA 11 PET/CT for Detection of Recurrent Prostate Cancer After Initial Therapy in Patients With Elevated PSA
68-Ga PSMA 11 PET/CT for Detection of Recurrent Prostate Cancer After Initial Therapy in Patients With Elevated PSA
Enrollment Status: Completed
Publish Date: January 13, 2022
Intervention Type: Procedure, Drug
Study Drug: Gallium Ga 68-Labeled PSMA-11
Study Phase: Phase 2/Phase 3
High Quality Imaging and Dosimetry of Yttrium-90 (90Y) SIRT Using a Digital PET/CT
High Quality Imaging and Dosimetry of Yttrium-90 (90Y) SIRT Using a Digital PET/CT
Enrollment Status: Completed
Publish Date: January 10, 2022
Intervention Type: Procedure, Device, Diagnostic test
Study Phase: Not Applicable
Quantitative Rest/Stress Cardiac Perfusion Digital PET/CT: Comparison Between Noninvasive Imaging and Invasive Coronary Angiography.
Quantitative Rest/Stress Cardiac Perfusion Digital PET/CT: Comparison Between Noninvasive Imaging and Invasive Coronary Angiography.
Enrollment Status: Completed
Publish Date: October 26, 2021
Intervention Type: Diagnostic test, Drug
A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer
A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer
Enrollment Status: Completed
Publish Date: June 14, 2021
Intervention Type: Diagnostic test, Drug
Study Phase: Phase 3
Targeted PET/CT and PET/MRI Imaging of Vascular Inflammation
Targeted PET/CT and PET/MRI Imaging of Vascular Inflammation
Enrollment Status: Withdrawn
Publish Date: May 21, 2021
Intervention Type: Drug, Procedure, Device
Study Phase: Phase 2
Comparison of PET/CT vs. PET/MRI
Comparison of PET/CT vs. PET/MRI
Enrollment Status: Completed
Publish Date: April 09, 2021
Intervention Type: Device, Drug
Study Phase: Phase 2
Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis
Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis
Enrollment Status: Completed
Publish Date: October 03, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy
Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy
Enrollment Status: Completed
Publish Date: September 18, 2019
18F-Florbetaben (Neuraceq®) PET/MRI Evaluation of Cardiac Amyloid
18F-Florbetaben (Neuraceq®) PET/MRI Evaluation of Cardiac Amyloid
Enrollment Status: Completed
Publish Date: July 17, 2019
Intervention Type: Drug
Study Phase: Early Phase 1
An Exploratory Study of the Role of 18F-FSPG PET/CT Imaging for Cancer Patients Receiving Therapy
An Exploratory Study of the Role of 18F-FSPG PET/CT Imaging for Cancer Patients Receiving Therapy
Enrollment Status: Completed
Publish Date: January 03, 2019
Intervention Type: Drug
Study Phase: Phase 2
Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer
Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer
Enrollment Status: Completed
Publish Date: October 31, 2018
68Ga DOTA-TATE PET/CT in the Evaluation of Patients With Somatostatin Receptor Positive Tumors
68Ga DOTA-TATE PET/CT in the Evaluation of Patients With Somatostatin Receptor Positive Tumors
Enrollment Status: No_longer_available
Publish Date: August 23, 2017
Intervention Type: Drug
Combined One Stop Shop NaF/FDG PET/MRI Evaluation of Response to Xofigo® in mCRPC Patients: A Pilot Study
Combined One Stop Shop NaF/FDG PET/MRI Evaluation of Response to Xofigo® in mCRPC Patients: A Pilot Study
Enrollment Status: Terminated
Publish Date: May 30, 2017
Intervention Type: Procedure, Drug
Study Phase: Phase 1
View 27 Less Clinical Trials

223 Total Publications

Correction to: Guiding principles on the education and practice of theranostics.
Correction to: Guiding principles on the education and practice of theranostics.
Journal: European journal of nuclear medicine and molecular imaging
Published: May 30, 2025
View All 223 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jagruti C. Shah
Radiology | Nuclear Medicine
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jagruti C. Shah
Radiology | Nuclear Medicine

Stanford Health Care

420 Broadway St, 
Redwood City, CA 
 (22.7 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jagruti Shah is a Radiologist and a Nuclear Medicine provider in Redwood City, California. Dr. Shah is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are WT1-Related Wilms Tumor Syndromes, Osteopenia, Melorheostosis with Osteopoikilosis, and Melorheostosis.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Guido A. Davidzon
Radiology | Nuclear Medicine
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Guido A. Davidzon
Radiology | Nuclear Medicine

Stanford Health Care

420 Broadway St, 
Redwood City, CA 
 (22.7 miles away)
650-723-4000
Languages Spoken:
English
Offers Telehealth

Guido Davidzon is a Radiologist and a Nuclear Medicine provider in Redwood City, California. Dr. Davidzon is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Neuroendocrine Tumor, Osteopenia, Melorheostosis, Melorheostosis with Osteopoikilosis, and Prostatectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Emily M. Webb
Radiology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Emily M. Webb
Radiology

University Of California San Francisco

2356 Sutter St, 
San Francisco, CA 
 (31.2 miles away)
415-476-1000
Languages Spoken:
English

Emily Webb is a Radiologist in San Francisco, California. Dr. Webb is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are WT1-Related Wilms Tumor Syndromes, Ureterocele, Boils, and Fibrolamellar Carcinoma.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Iagaru's expertise for a condition
ConditionClose
  • Elite
  • Neuroendocrine Tumor
    Dr. Iagaru is
    Elite
    . Learn about Neuroendocrine Tumor.
    See more Neuroendocrine Tumor experts
  • Distinguished
  • Melorheostosis
    Dr. Iagaru is
    Distinguished
    . Learn about Melorheostosis.
    See more Melorheostosis experts
  • Melorheostosis with Osteopoikilosis
    Dr. Iagaru is
    Distinguished
    . Learn about Melorheostosis with Osteopoikilosis.
    See more Melorheostosis with Osteopoikilosis experts
  • Osteopenia
    Dr. Iagaru is
    Distinguished
    . Learn about Osteopenia.
    See more Osteopenia experts
  • Advanced
  • Alveolar Soft Part Sarcoma
    Dr. Iagaru is
    Advanced
    . Learn about Alveolar Soft Part Sarcoma.
    See more Alveolar Soft Part Sarcoma experts
  • Cholangiocarcinoma (Bile Duct Cancer)
    Dr. Iagaru is
    Advanced
    . Learn about Cholangiocarcinoma (Bile Duct Cancer).
    See more Cholangiocarcinoma (Bile Duct Cancer) experts
  • Classical Hodgkin Lymphoma
    Dr. Iagaru is
    Advanced
    . Learn about Classical Hodgkin Lymphoma.
    See more Classical Hodgkin Lymphoma experts
  • Epithelioid Sarcoma
    Dr. Iagaru is
    Advanced
    . Learn about Epithelioid Sarcoma.
    See more Epithelioid Sarcoma experts
  • Fibrolamellar Carcinoma
    Dr. Iagaru is
    Advanced
    . Learn about Fibrolamellar Carcinoma.
    See more Fibrolamellar Carcinoma experts
  • Fibrosarcoma
    Dr. Iagaru is
    Advanced
    . Learn about Fibrosarcoma.
    See more Fibrosarcoma experts
View All 22 Advanced Conditions
  • Experienced
  • Acute Lymphoblastic Leukemia (ALL)
    Dr. Iagaru is
    Experienced
    . Learn about Acute Lymphoblastic Leukemia (ALL).
    See more Acute Lymphoblastic Leukemia (ALL) experts
  • Adrenal Cancer
    Dr. Iagaru is
    Experienced
    . Learn about Adrenal Cancer.
    See more Adrenal Cancer experts
  • Alagille Syndrome
    Dr. Iagaru is
    Experienced
    . Learn about Alagille Syndrome.
    See more Alagille Syndrome experts
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Iagaru is
    Experienced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • Ampullary Cancer
    Dr. Iagaru is
    Experienced
    . Learn about Ampullary Cancer.
    See more Ampullary Cancer experts
  • Caffey Disease
    Dr. Iagaru is
    Experienced
    . Learn about Caffey Disease.
    See more Caffey Disease experts
View All 46 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved